Online citations, reference lists, and bibliographies.
← Back to Search

Pathological Diagnosis Of Mesothelioma

G. Fontanini, G. Alí, R. Bruno
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The diagnosis of mesothelioma is one of the most difficult challenges faced by pathologists. Its histologic diagnosis is stepwise and should be based on morphological assessment, associated with clinical and radiological findings, and supported by immunohistochemistry as well as more recent molecular tests. This neoplasm displays a wide variety of histologic patterns and the major dilemmas consist in differential diagnosis with benign mesothelial proliferations and other mimicking malignant tumors.
This paper references
10.1002/1097-0142(19821015)50:8<1615::AID-CNCR2820500826>3.0.CO;2-K
Cystic mesothelioma of the peritoneum. A report of five cases and review of the literature
Y. Katsube (1982)
10.1016/J.LUNGCAN.2005.03.017
Implications of P16/CDKN2A deletion in pleural mesotheliomas.
M. Ladanyi (2005)
10.1038/modpathol.2011.146
A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma
Kyuichi Kadota (2012)
10.5858/arpa.2017-0124-RA
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
A. Husain (2018)
10.1097/00000478-200009000-00001
The separation of benign and malignant mesothelial proliferations.
A. Churg (2000)
10.1053/J.SEMDP.2006.06.002
Spindle cell tumors of the pleura: differential diagnosis.
M. Rdzanek (2006)
10.1097/00000478-200110000-00012
Well-Differentiated Papillary Mesothelioma
K. Butnor (2001)
10.1111/j.1349-7006.2012.02223.x
Frequent inactivation of the BAP1 gene in epithelioid‐type malignant mesothelioma
Yoshie Yoshikawa (2012)
10.1097/PAI.0b013e3182980544
p40 is the Best Marker for Diagnosing Pulmonary Squamous Cell Carcinoma: Comparison With p63, Cytokeratin 5/6, Desmocollin-3, and Sox2
Takahiro Tatsumori (2014)
10.1097/00000478-200105000-00007
Calretinin and Other Mesothelioma Markers in Synovial Sarcoma: Analysis of Antigenic Similarities and Differences With Malignant Mesothelioma
M. Miettinen (2001)
10.1097/JTO.0000000000000471
High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Masaki Nasu (2015)
10.21037/jtd.2017.10.88
Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.
R. Bruno (2018)
10.1016/j.humpath.2009.04.030
IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
K. Ikeda (2010)
10.1097/00000478-198810000-00001
Multicystic Mesothelioma: An Analysis of Pathologic Findings and Biologic Behavior in 37 Cases
S. Weiss (1988)
10.1016/j.lungcan.2013.12.009
How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
A. Husain (2014)
10.1043/1543-2165(2008)132[1062:IOPAPN]2.0.CO;2
Immunohistochemistry of pulmonary and pleural neoplasia.
M. Beasley (2008)
10.1016/J.EJCTS.2007.09.043
Localised malignant pleural mesothelioma: a separate clinical entity requiring aggressive local surgery.
A. Nakas (2008)
10.1097/PAS.0b013e31822a2481
The Fake Fat Phenomenon in Organizing Pleuritis: A Source of Confusion With Desmoplastic Malignant Mesotheliomas
A. Churg (2011)
10.1007/s00404-018-4728-2
Benign multicystic mesothelioma and peritoneal inclusion cysts: are they the same clinical and histopathological entities? A systematic review to find an evidence-based management
A. Rapisarda (2018)
10.1038/modpathol.2012.105
Deciduoid mesothelioma: report of 21 cases with review of the literature
N. Ordóñez (2012)
10.1097/00000478-199004000-00010
Pleural multicystic mesothelial proliferation. The so-called multicystic mesothelioma.
N. Ball (1990)
10.1097/PAS.0b013e318218985b
Oncofetal Protein IMP3, a New Diagnostic Biomarker to Distinguish Malignant Mesothelioma From Reactive Mesothelial Proliferation
M. Shi (2011)
10.5858/arpa.2013-0381-RA
Malignant Mesothelioma Diagnosis.
Qudsia Arif (2015)
10.1097/01.pas.0000165529.78945.dc
Localized Malignant Mesothelioma
T. Allen (2005)
10.1046/j.1365-2559.2003.01686.x
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2
R. Attanoos (2003)
10.1016/j.humpath.2014.03.006
Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study.
N. Ordóñez (2014)
10.18632/oncotarget.9686
Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis
Luigina Micolucci (2016)
10.1038/ng.855
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew J Bott (2011)
10.1016/j.athoracsur.2016.08.063
Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.
W. Vigneswaran (2017)
10.1097/JTO.0000000000000663
Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.
W. Travis (2015)
10.1016/j.critrevonc.2016.05.004
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
S. Novello (2016)
10.1046/J.1365-2168.2000.01571.X
Results of treatment of 33 patients with peritoneal mesothelioma
G. Sebbag (2000)
10.1097/PAS.0000000000000394
BAP1 Immunohistochemistry and p16 FISH to Separate Benign From Malignant Mesothelial Proliferations
B. Sheffield (2015)
10.1046/j.1365-2559.2003.01583.x
Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study
D. Lucas (2003)
10.1097/PAS.0b013e3182354a79
Well-Differentiated Papillary Mesothelioma of the Female Peritoneum: A Clinicopathologic Study of 26 Cases
A. Malpica (2012)
10.1001/ARCHSURG.1990.01410230071012
Primary malignant peritoneal mesothelioma. A report of seven cases and a review of the literature.
J. Asensio (1990)
10.1002/cncy.21342
The diagnosis of malignant mesothelioma in effusion cytology
A. Paintal (2013)
10.1038/modpathol.2013.34
Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma
N. Ordóñez (2013)
10.1016/j.jtho.2015.11.005
The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.
F. Galateau-Sallé (2016)
10.1111/pin.12453
BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests
T. Hida (2016)
10.1016/j.humpath.2012.05.014
Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update.
N. Ordóñez (2013)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
WHO classification of tumours of the lung, pleura, thymus and heart
W. Travis (2015)
10.1097/PAS.0000000000000529
Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens
H. Hwang (2016)
10.1097/JTO.0b013e318211127a
Pleomorphic Epithelioid Diffuse Malignant Pleural Mesothelioma: A Clinicopathological Review and Conceptual Proposal to Reclassify as Biphasic or Sarcomatoid Mesothelioma
Kyuichi Kadota (2011)
10.1002/dc.21398
Diagnostic usefulness of EMA, IMP3, and GLUT‐1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations
K. Ikeda (2011)
10.1097/00000478-199404000-00004
Localized Malignant Mesothelioma: A Clinicopathologic and Flow Cytometric Study
T. Crotty (1994)
10.1046/j.1365-2559.2002.01352.x
Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum
R. Attanoos (2002)
10.1016/S1055-3207(03)00045-0
A review of peritoneal mesothelioma at the Washington Cancer Institute.
P. Sugarbaker (2003)
10.1097/PAS.0b013e31826ab1c0
IMP3 and GLUT-1 Immunohistochemistry for Distinguishing Benign From Malignant Mesothelial Proliferations
A. Lee (2013)
10.1097/PAS.0000000000000616
BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas
H. Hwang (2016)
10.1097/PAT.0b013e32835bc848
A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit
A. Segal (2013)
10.1177/107327480601300402
Malignant pleural mesothelioma: a comprehensive review.
R. Ismail-Khan (2006)
10.1097/PAS.0b013e3182910c82
Diffuse Intrapulmonary Malignant Mesothelioma Masquerading as Interstitial Lung Disease: A Distinctive Variant of Mesothelioma
B. Larsen (2013)
10.1038/modpathol.3800544
The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study
N. Ordóñez (2006)
10.1002/1097-0142(19900115)65:2<292::AID-CNCR2820650218>3.0.CO;2-W
Well‐differentiated papillary mesothelioma of the peritoneum. A clinicopathologic study of 22 cases
D. Daya (1990)
10.1002/dc.21303
The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma
E. Rakha (2010)
10.1002/dc.21380
Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions
S. Lonardi (2011)
10.5858/arpa.2012-0112-ra
The Separation of Benign and Malignant Mesothelial Proliferations
A. Churg (2012)
10.1309/AJCP5KNL7QTELLYI
Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells.
H. Minato (2014)
10.1038/modpathol.2011.202
Mesotheliomas with small cell features: report of eight cases
N. Ordóñez (2012)
10.1097/01.pap.0000213007.48479.94
Podoplanin: A Novel Diagnostic Immunohistochemical Marker
N. Ordóñez (2006)
10.1038/modpathol.2009.180
Sarcomatoid mesothelioma: a clinical–pathologic correlation of 326 cases
S. Klebe (2010)
10.1016/j.humpath.2009.06.014
Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.
J. Bishop (2010)
10.1038/modpathol.2015.65
BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations
Marta Cigognetti (2015)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.1378/CHEST.102.3.790
Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases.
Z. Selçuk (1992)
10.1038/modpathol.2012.39
Pleomorphic mesothelioma: report of 10 cases
N. Ordóñez (2012)
10.1136/oem.2006.030155
Tumours of the Serosal Membranes. Armed Forces Institute of Pathology Atlas of Tumour Pathology, Fourth Series, Fascicle 3
A. Gibbs (2007)
10.1136/jclinpath-2012-201303
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
D. Henderson (2013)
10.1097/01.pap.0000201832.15591.1d
Value of Immunohistochemistry in Distinguishing Peritoneal Mesothelioma From Serous Carcinoma of the Ovary and Peritoneum: A Review and Update
N. Ordóñez (2006)
Simian virus 40-like DNA sequences in human pleural mesothelioma.
M. Carbone (1994)
10.1016/S0046-8177(87)80196-X
The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen.
E. Cibas (1987)
10.1002/1097-0142(19890915)64:6<1336::AID-CNCR2820640628>3.0.CO;2-X
Multilocular peritoneal inclusion cysts (So‐called cystic mesotheliomas)
M. J. Ross (1989)
10.1038/modpathol.2008.125
Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review
S. Klebe (2008)
10.1093/carcin/bgt166
Molecular pathogenesis of malignant mesothelioma.
Y. Sekido (2013)
10.1007/s00428-004-1062-9
Localised pleural malignant mesothelioma. Report of two cases simulating pulmonary carcinoma and review of the literature
S. Asioli (2004)
10.5858/arpa.2010-0604-RA
Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.
P. Betta (2012)
10.3109/01913129609016331
Mucin-positive epithelial mesotheliomas: a histochemical, immunohistochemical, and ultrastructural comparison with mucin-producing pulmonary adenocarcinomas.
S. Hammar (1996)
10.1016/j.lungcan.2016.12.017
Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
T. Hida (2017)
10.1136/jcp.2010.076794
FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma
C. Chung (2010)
10.1016/j.lungcan.2018.07.041
Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.
A. Churg (2018)
10.1097/00000478-198908000-00004
Peritoneal Malignant Mesothelioma versus Serous Papillary Adenocarcinoma: A Histochemical and Immunohistochemical Comparison
D. Bollinger (1989)
10.1002/cncr.10923
The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions
P. Illei (2003)
10.5858/arpa.2015-0240-SA
New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
A. Churg (2016)
10.1093/AJCP/110.2.191
The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining.
W. E. Mangano (1998)
10.4103/1742-6413.170726
Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology
A. Hjerpe (2015)
10.1309/AJCPOI1DESU8MTHZ
Mesothelial proliferations: useful marker is not the same as a diagnostic one.
A. Husain (2014)
10.1097/00000478-200404000-00013
Well-differentiated Papillary Mesothelioma of the Pleura: A Series of 24 Cases
F. Galateau-Sallé (2004)
10.1002/1097-0142(19840901)54:5<951::AID-CNCR2820540536>3.0.CO;2-A
Non‐asbestos‐related malignant mesothelioma. A review
J. T. Peterson (1984)



Semantic Scholar Logo Some data provided by SemanticScholar